• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Current status of drug repositioning in hematology
Expert Rev Hematol. 2021 Oct 16. doi: 10.1080/17474086.2021.1995348. Online ahead of print.ABSTRACTINTRODUCTION: Drug repositioning (DR) is defined as determining new therapeutic applications for existing drugs. This approach is advantageous over de novo drug discovery in accelerating clinical development, in terms of lower costs, a shortened development period, a well-known action mechanism, a feasible dosage, and an acceptable safety profile.AREAS COVERED: This work was aimed at reviewing agents with successful DR in hematology.EXPERT OPINION: Thalidomide and plerixafor have been successfully repositioned for treating mu...
Source: Expert Review of Hematology - October 18, 2021 Category: Hematology Authors: Akihiro Ohmoto Shigeo Fuji Source Type: research

Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysis.
CONCLUSION: Daratumumab is associated with lower risk of VTE in clinical trials. PMID: 32710431 [PubMed - as supplied by publisher]
Source: International Journal of Hematology - July 23, 2020 Category: Hematology Authors: Wang J, Kim Y Tags: Int J Hematol Source Type: research

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Curativestategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd
Conclusions: Although longer follow-up is required, this "curative strategy for high risk SMM" continues being encouraging with an acceptable toxicity profile. The study has met its primary endpoint. The depth of response improved over the treatment: 63% of patients who completed induction and ASCT achieved ≥CR with a MRD-ve rate of 55%.DisclosuresMateos: Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors ...
Source: Blood - November 21, 2018 Category: Hematology Authors: Mateos, M.-V., Martinez-Lopez, J., Rodriguez Otero, P., Ocio, E. M., Gonzalez, M. S., Oriol, A., Gutierrez, N. C., Paiva, B., Rios, R., Rosinol, L., Alvarez, M. A., Calasanz, M. J., Bargay, J., Gonzalez, A. P., Alegre, A., Escalante, F., Martinez, R., Pui Tags: 731. Clinical Autologous Transplantation: Results: Poster I Source Type: research

The Epidemiology and Clinical Associations of Stroke in Patients with Acute Myeloid Leukemia: A review of 10,972 admissions from the 2012 National Inpatient Sample
Conclusions Patients with AML have an elevated risk of CVA compared to all inpatients and mortality in this population is high. Better characterization of risk factors of stroke in this vulnerable population is still needed. Teaser Acute leukemia predisposes patients toward the development of stroke. The latter, while devastating clinically, has been infrequently studied. Our study, using the 2012 National Inpatient Sample, found a 50-fold increase in the risk of stroke as compared to all inpatient admissions with a corresponding 5.5-fold increased risk of mortality. Significant risk factors for the development of stroke i...
Source: Clinical Lymphoma Myeloma and Leukemia - September 21, 2017 Category: Cancer & Oncology Source Type: research